My research goal is to provide a robust molecular platform for accurate decision-making in early stage prostate cancer. I have spent my scientific training investigating how individual genes or groups of genes have driven prostate cancer behaviour. My PhD thesis investigated the role of HES6 as a transcriptional driver in castrate resistant prostate cancer – we found that this single gene fundamentally changed the nature of prostate cancer cells. During this time I was funded by the Cambridge Biomedical Research Centre (NIHR) and GlaxoSmithKline, and also by a Raymond and Beverly Sackler Studentship. Subsequently, I developed an interest in integrated genomics in prostate cancer risk stratification as well as disease modelling with patient derived xenografts. In October 2018, I commenced a five-year Cancer Research UK funded Clinician Scientist Fellowship to undertake the SPACE Study, a translational research programme centred on identification the ‘lethal clone’ in high risk localised prostate cancer incorporating integrated genomics of targeted biopsies, spatial transcriptomics of whole prostates and data-driven tracking of clonal phylogenetics including in micro-metastatic disease. I also have an interest in novel molecular imaging techniques such as PSMA PET-CT and their use in disease stratification and decision-making before, during and after radical therapies.